EWA
CTXR icon

EverSource Wealth Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

EverSource Wealth Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$8 – 3763
2024
Q3 		$8 Hold
1
– – ﹤0.01% 3029
2024
Q2 		$14 Hold
1
– – ﹤0.01% 3050
2024
Q1 		$12 Buy
+1
New +$18 ﹤0.01% 2887

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

EverSource Wealth Advisors's CTXR Position: Q4 2024 in Review

EverSource Wealth Advisors sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 1 share — an estimated $8 sold.

EverSource Wealth Advisors first reported a position in CTXR in Q1 2024 and held it in 3 quarters. The position peaked at $14 in Q2 2024. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • EverSource Wealth Advisors reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • EverSource Wealth Advisors sold 1 Citius Pharmaceuticals share in Q4 2024, an estimated $8.
  • EverSource Wealth Advisors first reported a position in Citius Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • EverSource Wealth Advisors's Citius Pharmaceuticals position peaked at $14 in Q2 2024.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on EverSource Wealth Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.